TORONTO, May 11 (Reuters) - The Canadian province of Ontario
will stop offering first doses of AstraZeneca's COVID-19
vaccine because of evidence that the risk of rare blood clots is
somewhat higher than previously estimated, provincial officials
said on Tuesday.
"This decision was made out of an abundance of caution due
to an observed increase in the rare blood clotting known as
vaccine-induced immune thrombotic thrombocytopenia," said Chief
Medical Officer David Williams.
"We are reviewing the data to consider options for the use
of AstraZeneca for second doses and more broadly moving
forward."
(Reporting by Moira Warburton in Vancouver and Allison Martell
in Toronto, Editing by Rosalba O'Brien)
Astrazeneca (AZN)
